-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Children's medicines refer to special medicines used by minors under 14 years of age
.
In recent years, with the continuous increase in the number of children in China and the number of hospital visits, the market for children's medicines in China has also begun to expand
.
According to statistics, the size of China’s children’s drug market in 2020 is 185.
6 billion yuan.
According to the current growth rate of the children’s drug market has always been higher than that of the overall drug market.
Reached 200 billion yuan
.
Although the market is improving, it should be noted that the long-standing problems of children's medicines in China's children's medicine market, such as fewer varieties, ambiguous dosages, and lack of specifications, are also restricting the development of the domestic children's medicine industry and related pharmaceutical companies
.
The analysis believes that there are two main reasons for this situation
.
On the one hand, the development of children's drugs is difficult, and the efficacy and safety requirements of children's drugs are higher, which increases the risk and difficulty of clinical trials, and it is difficult to recruit patients for clinical trials of children's drugs, thereby increasing the cost of research and development; on the other hand, On the one hand, it is because the types of medicines used by children are changeable, and it is difficult to deal with adverse reactions, and China has no special regulations on the use of medicines for children, and enterprises cannot obtain corresponding tax incentives and policy support
.
However, in recent years, relevant departments have issued a series of policies to promote the development of children's medicines.
The industry expects that the children's medicine market will continue to expand while the children's medicine industry is ushering in a policy dividend period
.
The main reason for this conclusion is that policy has always been a powerful driving force for industrial development
.
At present, policy guarantees have begun to promote the development of children's medicines to a certain extent
.
For example, since the State Council issued the "Outline for the Development of Children in China (2011-2020)" in 2011, the issue of drug accessibility for children has been raised to the national level for the first time, and now it involves the review and approval system, clinical trials and Policies in many aspects, including scientific standardization, research and innovation, are gradually improving the problem of children's drug use
.
Data shows that under the influence of the policy, there has been a significant increase in the development and review and approval of children's drugs in 2021.
.
According to incomplete statistics, more than 10 children's medicines have been approved for marketing since 2021
.
Among them, some drugs also provide better dosage forms, such as vigabatrin powder for the treatment of infantile spasms, and nitisinone capsules for the treatment of type 1 tyrosinemia
.
In addition, there are currently more than 40 new pediatric drugs in China at the stage of clinical approval and above
.
In terms of dosage form, new drugs under development are mainly in the form of granules, oral liquids, sprays and other suitable for children
.
On the whole, China's children's medicine market is ushering in new development opportunities
.
Especially under the policy-guided research and development of children’s drugs and the liberalization of the "three-child policy", the industry predicts that the market for children’s drugs may exceed 200 billion yuan, and will continue to maintain an average annual double-digit number for a long time to come.
The above growth rate
.
.
In recent years, with the continuous increase in the number of children in China and the number of hospital visits, the market for children's medicines in China has also begun to expand
.
According to statistics, the size of China’s children’s drug market in 2020 is 185.
6 billion yuan.
According to the current growth rate of the children’s drug market has always been higher than that of the overall drug market.
Reached 200 billion yuan
.
Although the market is improving, it should be noted that the long-standing problems of children's medicines in China's children's medicine market, such as fewer varieties, ambiguous dosages, and lack of specifications, are also restricting the development of the domestic children's medicine industry and related pharmaceutical companies
.
The analysis believes that there are two main reasons for this situation
.
On the one hand, the development of children's drugs is difficult, and the efficacy and safety requirements of children's drugs are higher, which increases the risk and difficulty of clinical trials, and it is difficult to recruit patients for clinical trials of children's drugs, thereby increasing the cost of research and development; on the other hand, On the one hand, it is because the types of medicines used by children are changeable, and it is difficult to deal with adverse reactions, and China has no special regulations on the use of medicines for children, and enterprises cannot obtain corresponding tax incentives and policy support
.
However, in recent years, relevant departments have issued a series of policies to promote the development of children's medicines.
The industry expects that the children's medicine market will continue to expand while the children's medicine industry is ushering in a policy dividend period
.
The main reason for this conclusion is that policy has always been a powerful driving force for industrial development
.
At present, policy guarantees have begun to promote the development of children's medicines to a certain extent
.
For example, since the State Council issued the "Outline for the Development of Children in China (2011-2020)" in 2011, the issue of drug accessibility for children has been raised to the national level for the first time, and now it involves the review and approval system, clinical trials and Policies in many aspects, including scientific standardization, research and innovation, are gradually improving the problem of children's drug use
.
Data shows that under the influence of the policy, there has been a significant increase in the development and review and approval of children's drugs in 2021.
.
According to incomplete statistics, more than 10 children's medicines have been approved for marketing since 2021
.
Among them, some drugs also provide better dosage forms, such as vigabatrin powder for the treatment of infantile spasms, and nitisinone capsules for the treatment of type 1 tyrosinemia
.
In addition, there are currently more than 40 new pediatric drugs in China at the stage of clinical approval and above
.
In terms of dosage form, new drugs under development are mainly in the form of granules, oral liquids, sprays and other suitable for children
.
On the whole, China's children's medicine market is ushering in new development opportunities
.
Especially under the policy-guided research and development of children’s drugs and the liberalization of the "three-child policy", the industry predicts that the market for children’s drugs may exceed 200 billion yuan, and will continue to maintain an average annual double-digit number for a long time to come.
The above growth rate
.
